Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-114 in PTSD
NCT05260541Phase 2Terminated
- Sponsor
- Praxis Precision Medicines
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of PRAX-114 in post-traumatic stress disorder (PTSD), sponsored by Praxis Precision Medicines. Started Jan 2022; status: terminated.
02
Drugs
PRAX-114
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05260541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260541.